DelveInsight’s, “Alzheimer’s Disease Pipeline Insights, 2022,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Alzheimer’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Alzheimer’s Disease Pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Alzheimer’s Disease NDA approvals (if any), and product development activities comprising the technology, Alzheimer’s Disease collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Alzheimer’s Disease Pipeline Insight Report
To explore more information on the latest breakthroughs in the Alzheimer’s Disease Pipeline treatment landscape of the report, click here @ Alzheimer’s Disease Pipeline Outlook
Alzheimer’s Disease Overview
Alzheimer’s Disease is a slowly progressive brain disease that begins many years before symptoms emerge. It is the most common cause of dementia, accounting for an estimated 60% to 80% of cases. The hallmark pathologies of Alzheimer’s disease are the accumulation of the protein fragment beta‐amyloid (plaques) outside neurons in the brain and twisted strands of the protein tau (tangles) inside neurons. These changes are accompanied by the death of neurons and damage to brain tissue. On the basis of severity, this degenerative disease can be classified as mild, moderate, and severe.
Recent Breakthroughs of Alzheimer’s Disease Treatment Landscape
Request a sample and discover the recent advances in Alzheimer’s Disease Ongoing Clinical Trial Analysis and Medications, click here @ Alzheimer’s Disease Treatment Landscape
Alzheimer’s Disease Emerging Drugs Profile
BAN2401: Eisai
BAN2401 is the humanized IgG1 version of the mouse monoclonal antibody mAb158, which selectively binds to large, soluble Aβ protofibrils. BAN2401 selectively binds to neutralize and eliminate toxic Aβ protofibrils that are thought to be a causative factor for Alzheimer’s Disease. Eisai obtained the global rights to study, develop, manufacture and market BAN2401 for the treatment of Alzheimer’s disease pursuant to an agreement concluded with BioArctic in December 2007.
Gantenerumab: Hoffmann-La Roche
Gantenerumab is an investigational therapy designed to bind more specifically to aggregated forms of beta-amyloid and remove beta-amyloid plaques. Gantenerumab was originally developed by Chugai Pharmaceuticals, which is now part of Hoffmann-La Roche. This treatment is administered as an injection under the skin, is now being developed by Hoffmann-La Roche in collaboration with MorphoSys.
Alzheimer’s Disease Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the therapies for Alzheimer’s Disease (AD). The companies which have their Alzheimer’s Disease (AD) drug candidates in the most advanced stage, i.e. phase III include, Eisai.
Scope of the Alzheimer’s Disease Pipeline Report
Table of Content
Got Queries? Find out the related information on Alzheimer’s Disease Mergers and acquisitions, Alzheimer’s Disease Licensing Activities @ Alzheimer’s Disease Emerging Drugs, and Recent Trends
Trending Reports- Stem Cell Market | Asperger Syndrome Market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NV 89107Country: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services